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Abstract 
 
Agricultural workers are exposed to folpet but biomonitoring data are limited. Phthalimide 
(PI), phthalamic acid (PAA) and phthalic acid (PA) are the ring metabolites of this fungicide 
according to animal studies but they have not yet been measured in human urine as 
metabolites of folpet, only PA as a metabolite of phthalates. The objective of this study was 
thus to develop a reliable gas chromatography – tandem mass spectrometry (GC-MS) method 
to quantify the sum of PI, PAA and PA metabolites ring-metabolites of folpet in human urine. 
Briefly, the method consisted of adding p-methylhippuric acid as an internal standard (IS), 
performing an acid hydrolysis at 100°C to convert ring-metabolites into PA, purifying 
samples by ethyl acetate extraction and derivitazing with N,O-bis(trimethylsilyl)trifluoro 
acetamide (BSTFA) prior to GC-MS analysis. The method had a detection limit of 60.2 
nmol/L (10 ng/mL); it was found to be accurate (mean recovery of 97%), precise (inter- and 
intra-day percentage relative standard deviations < 13%) and with a good linearity 
(R
2 
> 0.98). Validation was conducted using unexposed person urines spiked at concentrations 
ranging from 4.0 to 16.1 µmol/L, along with urine samples of volunteers dosed with folpet 
and of exposed workers. The method proved to be i) suitable and accurate to determine the 
kinetic profile of PA equivalents in the urine of volunteers orally and dermally administered 
folpet and ii) relevant for the biomonitoring of exposure in workers. 
 
 
Keywords Phthalic acid · Phthalamic acid · Folpet · Human urine · Biological monitoring 
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Introduction 
 
Folpet, or N-trichloromethyl-thio-phthalimide (CAS number 133-07-3), has extensive 
application as a contact fungicide in a variety of fruit and vegetable crops or vineyards. 
Although a large number of workers use or are in contact with folpet, there is a paucity of data 
on the extent of occupational exposure to this compound. Some environmental measurements 
have been conducted [1] but only one study performed a biomonitoring of exposure to folpet 
in pregnant women through phthalimide (PI) measurements [2]. 
 
Folpet metabolism is however well characterized in animals and in vitro studies [3-7]. 
According to these studies, folpet is rapidly metabolized to PI and thiosphogene, an unstable 
metabolite which reacts with cysteine or gluthathione to form thiazolidine-2-thione-4-
carboxylic acid (TTCA). Phthalimide is also rapidly hydrolyzed to phthalamic acid (PAA), 
and in turn to phthalic acid (PA). The chemical structures of folpet and of its ring metabolites 
are displayed in Fig. 1. 
 
According to Chasseaud et al. [4;5;8] and Canal-Raffin et al. [3], the main ring-metabolite of 
folpet is PAA in rats following an oral, intratracheal or intraperitoneal administration. More 
specifically, Chasseaud et al. [5;8] observed that 80% of a labeled 
14
C-folpet dose orally 
administered to rats was recovered as PAA in urine. Canal-Raffin et al. [3] reported that PI 
was rapidly metabolized to PAA in plasma when folpet was intraperitoneally and 
intratracheally administered to rats. 
 
To quantify PAA, Canal-Raffin et al. [3] analyzed rat plasma by high-performance liquid 
chromatography with UV detection (HPLC-UV) after specific solid-phase extraction, but they 
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did not measure the metabolite in urine. Nevertheless, as determined by Bray et al. [9], PAA 
is a very unstable compound in urine, which has to be precisely extracted at pH 8.3 and is 
transformed to PA in acidic conditions (pH 2-3). Namely, under electron impact ionization 
(EI) for GC-MS analysis, water loss is induced and the neutral compound PAA can rearrange 
to PI, phthalic anhydride or phthalic acid [10;11]. It is thus more convenient to transform PI 
and PAA metabolites of folpet to PA in acid conditions, and to measure total PA equivalents 
in urine as a biomarker of exposure. 
 
Analytical methods have already been developed to quantify PA as a urinary metabolite of 
phthalates, because it is also the final hydrolysis product of phthalates [12-16], but no method 
has been published for the quantification of total PA equivalents as a biomarker of folpet 
exposure to our knowledge. Therefore, the objectives of this study were i) to measure total PA 
equivalents in urine as a biomarker of folpet exposure by adapting existing gas 
chromatography - mass spectrometry [GC-MS] methods after oxidation of PI and PAA and 
trimethylsylation of PA molecule, and ii) to use this method to quantify the urinary excretion 
of total PA equivalents in volunteers exposed to folpet as well as iii) to assess worker 
exposure to this fungicide through biomonitoring. 
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Materials and methods 
 
Chemicals and reagents 
Phthalic acid (1,2-Benzenedicarboxylic acid), phthalamic acid (benzoic acid,2-
aminocarbonyl), phthalimide and p-methylhippuric acid used as reference standards (>99% 
purity) were obtained from Sigma-Aldrich (Buchs, St Gallen, Switzerland). Other chemicals 
and reagents such as HPLC-grade acetonitrile, dimethylformamide, ethyl acetate, N,O-
bis(trimethylsilyl)trifluoro acetamide (BSTFA), hydrochloric acid and sodium chloride 
(NaCl) were also purchased from Sigma-Aldrich (Buchs, St Gallen, Switzerland). Purified tap 
water by a TKA GenPure (Niederelbert, Germany) was used. 
 
Standard preparation 
Stock standard solutions 
A stock standard solution of 130 mg/L (0.8 mmol/L) of PA was prepared by dissolving 13 mg 
of PA in 100 mL of 1% (v/v) dimethylformamide in acetonitrile. Similarly, a stock standard 
solution of the internal standard (IS) p-methylhippuric acid of 100 mg/L (0.5 mmol/L) was 
prepared by dissolving 10 mg of p-methylhippuric acid in 100 ml of 1% (v/v) 
dimethylformamide in acetonitrile. In addition, to measure the fraction of PI and PAA 
converted to PA with this analytical method, two individual stock standard solutions of 112 
mg/L (0.8 mmol/L) of PI and 114 mg/L (0.7 mmol/L) of PAA were prepared by dissolving 
11.2 mg of PI and 11.4 mg of PAA, respectively, in 100 mL of 1% (v/v) dimethylformamide 
in acetonitrile. The stock solutions were stored at -20°C in glass containers until used. 
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Calibration curves 
Calibration curves were prepared by spiking aliquots of pooled urine from unexposed persons 
at different concentrations of PA and a constant concentration of IS. Working solutions of PA 
at 26 mg/L (0.16 mmol/L) and IS at 20 mg/L (0.1 mmol/L) were thus prepared daily from 
stock solutions diluted 5-fold in water. Calibration curves of PA consisted of urine from 
unexposed persons spiked at six concentration levels prepared in duplicates: 0, 0.67, 1.3, 2.0, 
2.3 and 2.7 µg/mL (0, 4.0, 8.1, 12.1, 14.1 and 16.1 µmol/L). For each level, 2 mL of urine 
were spiked with a constant volume of 100 µL of IS working solution as well as defined 
volumes of PA working solution and completed with water to obtain a final volume of 2.3 
mL. 
 
Sample treatment 
The analytical approach used to quantify total urinary PA equivalents consisted of an acid 
hydrolysis, solvent extraction and derivatization with BSTFA followed by gas 
chromatography – mass sprectrometry (GC-MS) analysis. Sample preparation was adapted 
from method of Mettang et al. [14]. Two-mL aliquots of urine were transferred into screw-cap 
reaction vials and spiked with 100 µL of internal standard working solution (20 mg/L or 0.1 
mmol/L) and 200 µL of water. An acid hydrolysis was then performed by adding HCl (300 
µL at 12 N) and heating at 100°C for 12 h. After cooling, samples were extracted twice with 2 
mL of ethyl acetate by agitating for 15 min and centrifuging for 10 min at 2500 rpm. Upper 
organic layers were transferred into glass tubes. Extracts were evaporated to dryness under a 
gentle nitrogen flow at 40°C to concentrate samples. Residues were resuspended in 300 µL of 
ethyl acetate; 30 µL of BSTFA were added and samples were heated at 60°C for 60 min to 
convert total PA equivalents and p-methylhippuric acid IS into trimethylsilyl phthalic acid 
(TMS-PA) and trimethylsilyl p-methylhippuric acid (TMS-IS), respectively, by replacement 
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of the labile hydrogen of the hydroxy groups. Before transferring derivatized extracts to vials 
for GC-MS analysis, extracts were cooled for a 2-h period. 
 
Instrumental analysis 
Analyses were carried out on a HP 5973 gas chromatograph equipped with a mass selective 
detector Agilent MSD-G1098A and a CP-SIL 8 CB fused silica capillary column (60 m 
length, 1 µm film thickness, 250 µm I.D.). Helium was used as a carrier gas at a 27 cm/s 
linear velocity. The injector was set to a temperature of 260°C and a constant column flow 
rate was held at 1.0 mL He/min. The transfer line was set at 250°C and the ion source at 
230°C. The GC oven temperature program was set initially at 200°C for 3 min; it was then 
increased to 260°C at 30°C/min, held for 11 min, and finally increased to 280°C at 35°C/min 
and held for 4 min. The mass detector was operated in single ion monitoring mode for 
quantification and fragment ions were generated by electron impact ionization at 70 eV. The 
fragments analyzed were m/z 295 for TMS-PA (qualitative ions were m/z 221 and 147) and 
m/z 220 (qualitative ions were m/z 177 and 119) for TMS-IS. Two µL were injected onto the 
GC with an Agilent auto-sampler using a 5 mL/min split. Under these conditions, retention 
times were 10.6 min for TMS-PA and 16.0 min for TMS-IS. 
 
 
Quantification of PA 
Quantification of PA was carried out using standard calibration curves in urine. This was 
achieved by plotting the response factors as a function of the six standard concentration levels 
of PA (0, 0.67, 1.3, 2.0, 2.3 and 2.7 µg/mL or 0, 4.0, 8.1, 12.1, 14.1 and 16.1 µmol/L). The 
response factors were the peak-height ratios of TMS-PA to TMS-IS. 
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Estimation of the fraction of PI and PAA converted to PA 
The fraction of PI and PAA converted to PA with the analytical processing used was also 
determined. Aliquots of urine from an unexposed person were independently spiked with 
standard solutions of 22.5 mg/L of PI or 22.8 mg/L of PAA (stock standard solutions diluted 
5-fold) at six concentration levels prepared in duplicates: 0, 0.56, 1.12, 1.69, 1.97 and 2.25 
g/L (0, 3.8, 7.6, 11.5, 13.4 and 15.3 mmol/L) for PI and 0, 0.57, 1.14, 1.71, 1.99 and 2.28 g/L 
(0, 3.4, 6.9, 10.3, 12.1 and 13.8 mmol/L) for PAA. These samples were then treated using the 
method described previously for the quantification of TMS-PA. The fraction of PI and PAA 
converted to total PA equivalents (expressed as a percentage) was calculated using the 
following equation: 
Fraction of PI and PAA converted to PA %
  
Amounts of PA in extracts of spiked samples (mol)
Added amounts of PI or PAA in urine samples (mol)
 × 100 
 
Method validation 
In order to validate the method, the following criteria were verified: limit of detection (LOD), 
limit of quantification (LOQ), linearity, intra- and inter-day precision, accuracy, recovery and 
stability. In addition, internal quality control (QC) urinary samples were prepared from a pool 
of urine from unexposed individuals spiked at two levels of concentrations (1 and 2.5 µg/mL 
or 6 and 15 µmol/L). From this pool, 6-mL aliquots were prepared and stored at -20°C. 
During each daily run, QC samples were analyzed in triplicates, as unknown samples. 
 
Specificity of the method was confirmed by verifying the absence of interferences on the 
chromatograms obtained from urine samples of unexposed individuals (n = 22). The LOD 
was established as three times the signal-to-noise ratio for the specific ions m/z 295 and m/z 
220 and the LOQ as ten times the signal-to-noise ratio. Linearity was calculated from 
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regression parameters of 22 calibration curves, by the least square fit method. Results were 
expressed using the mean of coefficient of determination (R
2
). 
 
To assess intra- and inter-day variations, the precision and accuracy were calculated from 
replicate analysis of previously prepared QC samples and of daily prepared aliquots of a pool 
of urine from unexposed individuals spiked with PA at five different levels. The intra-day 
variation was estimated by the repeatability of triplicates of QC samples and of duplicates of 
each spiking level prepared daily and analyzed the same day. The inter-day variation was 
estimated by the reproducibility of these previous samples on 22 consecutive days. 
 
Precision, expressed as percentage of relative standard deviation (% RSD), was determined as 
the ratio of standard deviation to mean of the response factor for each spiking level (QC 
samples and prepared daily spiked samples) multiplied by 100. Accuracy, expressed in 
percentage, was calculated as follows: 
average measured amounts of PA  known spiking amounts of PA
known spiking amounts of PA
  100 
 
Recovery of PA in urine after extraction and derivatization was calculated for each spiking 
level by the ratio of measured amounts of PA in extracts to the theoretical spiked amounts in 
urine of unexposed individuals and expressed as a percentage. 
 
The stability of PA in urine was ascertained by analyzing every day over a 22-day period an 
aliquot of QC samples kept at -20
o
C, and thawed daily and processed. The stability of PA 
equivalents in urinary samples of workers exposed to folpet was also determined. More 
specifically, the effect of preservation of urine samples at 4
0
C over a 24-h-period was tested. 
11 
 
Two urine samples of workers thawed, processed and analyzed for PA equivalents in a given 
run were thus kept at 4°C, processed and reanalyzed during the following run. 
 
Application of the method 
The method was used to determine total urinary amounts of ring-metabolites of folpet in 
exposed individuals. First, concentrations of total PA equivalents were determined in all 
urines collected repeatedly and at predetermined times over a 96-h period following an oral 
and dermal administration of 1 and 10 mg/kg of folpet, respectively, in five volunteers (the 
same five volunteers were used for the oral and dermal dosing).  
 
Secondly, concentrations of PA equivalents were measured in all complete urine voids 
collected over a 7-day period following a folpet treatment and sequences of harvesting in 
grapegrowers (n = 3). Each worker collected i) a pre-seasonal complete first-morning void, 
hence a urine sample prior to folpet spraying and harvesting season, ii) all complete urine 
voids prior to and during a typical workweek following a folpet spraying, and iii) all complete 
urine voids prior to and during a typical workweek involving harvest activities. During 
spraying period, the three workers applied folpet only on the first workday; during harvest 
activities period, workers 1 and 3 were in the treated area only on workday 1 while worker 2 
harvested from workdays 1 to 3. 
 
The Permanent Ethical Committee of Clinical Research of the Faculty of Biology and 
Medicine of the University of Lausanne and of the Research Ethical Committee of the Faculty 
of Medicine of the University of Montreal approved the protocol, and all participants gave 
their written informed consent, and were acquainted with the risks of participating and their 
right to withdraw from the study at all time. The volunteers administered folpet received a 
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small monetary compensation for their time and any inconvenience caused, as suggested by 
the Ethics Committee who considered the study as restrictive. Conversely, workers were not 
compensated. 
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Results and discussion 
 
Method development 
To optimize the method of Mettang et al. [17] for the specific analysis of total PA equivalents 
as a biomarker of exposure to folpet, several preliminary tests were performed: 1) the 
verification of potential contamination of laboratory materials by phthalates, 2) the selection 
of a proper IS, 4) the effect of NaCl addition prior to extraction and 4) the establishment of 
the most efficient type of hydrolysis. Firstly, to verify if that laboratory materials (i.e. vials, 
caps, pipettes) were a contamination source of PA during sample processing, triplicate 
controls with water and ethyl acetate were subjected to the processing procedure; no PA peak 
was observed after analysis. Secondly, potential internal standards were also tested. Four 
deuterium phthalic acids (PA-d) were initially considered, but the separation of PA and PA-d 
on the GC column was insufficient to differentiate both peaks on chromatograms. Para-
methylhippuric acid was then assayed because the molecule comprised a carboxylic acid and 
an amine group, and finally selected. Thirdly, to improve extraction, the effect of adding NaCl 
to urine samples prior to extraction and analysis was compared with results obtained after 
analysis of the same urine samples without NaCl addition. The results are presented in Table 
1 and show that extraction efficiency was better without NaCl addition. 
 
Lastly, efficiency of acid hydrolysis as compared to enzymatic hydrolysis was tested. This 
latter step was described by several authors for the quantification of phthalates [14;17-23]. To 
perform enzymatic hydrolysis, 20 µL of β-glucuronidase-arylsulfatase were added to 2 mL of 
four urine samples from one person administered folpet and samples were heated at 37°C for 
12 h; for acid hydrolysis, 500 µL of HCl 2N were added and samples were heated either at 
37°C or 100°C for 12 h. As shown in Table 2, higher concentrations of total PA equivalents 
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were observed after acid hydrolysis at 100°C than at 37°C, while enzymatic hydrolysis 
appeared inadequate and insufficiently strong to transform PI and PAA into PA. Pfäffli [24] 
previously reported that enzymatic hydrolysis was unnecessary because PA appears to be 
mainly excreted as free acid and not partly conjugated and excreted as glucuronide. Table 3 
also shows that when spiking urine samples with PAA and PI, PAA is virtually all converted 
to TMS-PA (100%) and half of PI was converted to TMS-PA (≈50%) following an acid 
hydrolysis at 100°C. Thus, acid hydrolysis was selected for the quantification of total PA 
equivalents. Even if PI was not completely converted to TMS-PA by acid hydrolysis, it is a 
very minor metabolite of folpet as compared to PAA according to in vivo studies in rats 
exposed to folpet [3-8].  
 
Representative chromatograms of TMS-PA and TMS-IS in urine from an unexposed 
individual spiked with 12.1 µmol/L of PA and 6.72 µmol/L of IS, as well as the mass spectra 
and the molecule structure of both derivatives are presented in Figure 2. These 
chromatograms were obtained with the optimized method after acid hydrolysis, solvent 
extraction and derivatization. Chromatograms show very limited background interference. 
Clean chromatograms were observed not only for spiked and non-spiked urines from 
unexposed individuals, but also for samples from volunteers dosed with folpet and from 
workers, as displayed in Fig. 3. Therefore, analytical conditions were specific to quantify 
TMS-PA as the sum of total ring-metabolites folpet. 
 
It is to be noted that TMS-PA was detectable in urine samples of unexposed persons, as 
illustrated in Fig. 3b. Hence, an average PA concentration (± SD) of 285 ± 150 nmol/mmol 
creatinine (492 ± 275 ng/mL) was obtained in the urine of unexposed individuals (n = 10) and 
186 ± 79.7 nmol/mmol creatinine (507 ± 280 ng/mL) in pre-seasonal urines of workers 
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exposed to folpet (n = 3). These values are equivalent to PA concentrations determined by 
Pfäffli [24] in pre-shift urines of workers exposed to phthalic anhydride (490 nmol/mmol 
creatinine) and in urines of occupationally unexposed people (0.34 µmol/mmol creatinine). 
Similarly, in biomonitoring studies of phthalates, Jönsson et al. [25], Kato et al. [19] and 
Vermeulen et al. [26] reported also relatively high PA baseline levels in unexposed people or 
in workers during a non-exposure period. These levels were on average lower than those 
found in our study; however, large interindividual variability was found. Namely, Jönsson et 
al. [25] reported a mean PA concentration of 94 nmol/mmol creatinine (95
th
 percentile) in 
urine samples from 234 Swedish men, with a maximum concentration of 2100 nmol/mmol 
creatinine; Kato et al. [19] measured a median PA concentration of 6.19 ng/mL in 43 
unexposed and anonymous adults with a range of 1.54 to 44.4 ng/mL (creatinine was not 
measured in this study); Vermeulen et al. [26] obtained a median PA concentration of 77 
ng/mL (47 nmol/mmol creatinine) in Sunday urine samples of rubber workers with a range of 
4 to 2449 ng/mL (2.44 to 1495 nmol/mmol creatinine). This baseline is unavoidable because 
phthalates are ubiquitous in the environment and exposure can occur from various sources 
[12;14-31]; exposure to folpet in the general population can also occur through the diet, thus 
also contributing to baseline levels. Biomonitoring results should thus be interpreted with 
caution in non-occupationnally exposed invididuals. However, these studies observed higher 
PA concentrations when people were occupationally exposed to phthalates.  
 
Method validation 
To validate the robustness of the current method, we evaluated its linearity, LOD, LOQ, intra- 
and inter-day precision and accuracy, recovery and stability using a pool of urine from 
unexposed individuals spiked at five different levels and two QC samples. 
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All calibration curves (n = 22) were linear within the spiking range in urine of 0.67 to 2.7 
µg/mL (4.0 to 16.1 µmol/L) with a mean equation of y = 0.957x + 0.088 and a coefficient of 
determination of 0.98. The LOD and LOQ of PA in urine were 10 ng/mL (60.2 nmol/L) and 
33 ng/mL (199 nmol/L), respectively. In comparison with methods developed for the analysis 
of PA as a biomarker of phthalate exposure, our method had a better LOD than the one 
obtained with the liquid chromatography – tandem mass spectrometry (LC/MS/MS) method 
described by Jönsson et al. [25] (LOD = 15 ng/mL or 90.3 nmol/L) or the GC-MS method of 
Pfäffli [24] (LOD = 100 ng/mL or 602 nmol/L) and a LOD similar to the one reported by Lim 
et al. [13] with a HPLC/UV method (LOQ = 100 ng/mL or 602 nmol/L). However, Kato et al. 
[19], Silva et al. [22] and Vermeulen et al. [26] reported LC/MS/MS methods for the 
quantification of PA metabolites of phthalates with a slightly better LOD (LOD of 0.42, 1.59 
and 5 ng/mL or 2.53, 9.57 and 30.1 nmol/L, respectively). Nonetheless, to determine 
phthalate exposure to date, specific metabolites (i.e. monoesters and oxidation products) are 
preferably measured instead of PA, which is a common final metabolite of many phthalates 
[13; 17-18; 28-29]. 
 
Results for precision and accuracy of the method are summarized in Table 4 for each of the 
five daily prepared spiking levels of aliquots of a pool of urine from unexposed individuals as 
well as for two pre-prepared QC samples. Results indicate that urinary PA was reliably 
measured in urine because the intra- and inter-day precision expressed by the percent relative 
standard deviation (% RSD) was less than 13% overall (less than 10% for spiking amounts 
higher than 2 nmol), and accuracy established by the percent relative error (% RE) was less 
than 10%. 
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Table 4 also reveals an excellent recovery of PA in extracts after acid hydrolysis, solvent 
extraction and derivatization of urine samples spiked with PA. Hence, the mean (± SD) 
recovery of PA (all spiked levels combined) was 97.5 ± 8.8%, indicating that very little PA 
was lost during processing. 
 
QC samples kept at -20
o
C and thawed daily and processed over a 22-day period also appeared 
stable; this is evident when comparing mean intra-day variation in recovered PA amounts to 
mean inter-day variation (Table 4). Likewise, PA was stable in urine samples of workers 
exposed to folpet. A coefficient of variation ranging from 6.9 to 13.3% was obtained when 
two aliquots of the same urine collection of two workers kept at 4
o
C for 24 h were processed 
and analyzed during the following run. 
 
Application of the method to biomonitoring 
To further validate the method and verify that total ring-metabolites of folpet (i.e. total PA 
equivalents) could be efficiently quantified in the urine of individuals exposed to folpet, 
urines of volunteers orally and dermally dosed with folpet as well as urines of grapegrowers 
during a typical work week were analyzed. 
 
The mean concentration-time profiles of total PA equivalents in the urine of volunteers 
following an oral and dermal administration are presented in Fig. 4. Although there was a 
background PA level, it was easy to document the human toxicokinetics of this biomarker of 
exposure [32-33]. Briefly, PA had a relatively short elimination half–life in urine and it was 
similar for both exposure routes, hence 27.6 h and 29.6 h for oral and dermal routes, 
respectively. Similarly, Table 5 displays pre- and post-shift urinary levels of total PA 
equivalents in workers exposed to folpet during and following spraying or harvest activities. 
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PA was measurable in all urine samples of workers and an increase in excretion was observed 
for most workers following spraying or harvest activities. According to these results, workers 
were more exposed during spraying activities than during harvest activities. Consequently, the 
method proved to be suitable to quantify actual daily exposures to folpet in workers. 
 
 
Conclusion 
 
In summary, the method was found to have a LOD of 60.2 nmol/L, an excellent recovery 
(mean of 97%), a good linearity with a R
2
 superior to 0.98. It is also precise with an inter- and 
intra-day percentage relative standard deviations inferior to 13%. In addition, with this 
method, only a small urine volume is needed (2 mL) and sample treatment is straightforward. 
Moreover, our results evidenced that the current GC-MS method was reliable and accurate to 
quantify total PA equivalents the in urine of individuals dosed with folpet as well as relevant 
to assess worker exposure using biomonitoring.  
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Table 1 
Comparison of PA concentration (nmol/mL) measured in four urine samples collected at 
different time points in a same individual experimentally administered folpet by the oral 
route, with or without the addition of sodium chloride prior to extraction. 
 
Urine sample
b
 
PA concentrations (nmol/mL)
a
 
Extraction
 
 without NaCl with NaCl
c
 
Urine 1 4.60 3.91 
Urine 2 33.6 27.2 
Urine 3 122 103 
Urine 4 36.8 35.4 
 
a
 Urinary concentrations observed following sample processing as described in Materials and 
Methods but with or without addition of sodium chloride prior to extraction. 
b
 Urine samples collected at four different time periods in one volunteer orally administered 
folpet (1 mg/kg dose). 
c
 250 mg of sodium chloride (NaCl) were added to 2 mL of urine prior to first extraction. 
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Table 2 
Comparison of PA concentration (nmol/mL) measured in four urine samples collected at 
different time points in a same individual experimentally administered folpet by the oral route 
following an enzymatic hydrolysis at 37
o
C or an acid hydrolysis at 37°C or 100°C. 
 
 PA concentrations (nmol/mL)
a
 
Urine sample
b 
Enzymatic 
Hydrolysis
c
 
Acid hydrolysis 
at 37°C
d
 
Acid hydrolysis 
at 100°C
e 
Urine 1 2.15 2.26 4.03 
Urine 2 2.62 12.5 13.7 
Urine 3 2.62 16.5 17.2 
Urine 4 2.82 24.2 24.3 
 
a
 Urinary concentrations observed following sample processing as described in Materials and 
Methods but with either enzymatic hydrolysis at 37
o
C or acid hydrolysis at 37°C or 100°C. 
b
 Urine samples collected at four different time periods in one volunteer orally administered 
folpet (1 mg/kg dose). Urines were different from those used to test the effect of addition of 
NaCl on extraction efficiency (Table 1). 
c
 20 µL of glucuronidase-arylsulfatase were added to 2 mL of urine and samples were heated 
at 37°C for 12 h. 
d
 500 µL of HCl 2N were added to 2 mL of urine and samples were heated at 37°C for 12 h. 
e
 500 µL of HCl 2N were added to 2 mL of urine and samples were heated at 100°C for 12 h. 
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Table 3 
Conversion of PAA and PI as TMS-PA (expressed as a percentage) after sample processing 
(acid hydrolysis, extraction and derivatization) of aliquots of a same urine from an unexposed 
subject spiked at five different levels (nmol added). 
 
Spiked 
metabolite 
Amount added
a 
(nmol) 
Amount of TMS-PA found
b 
(nmol) 
Conversion
c 
(%) 
PAA 6.90 6.42 93.1 
 13.8 14.3 104 
 20.7 20.7 99.8 
 24.1 24. 6 102 
 27.6 27.9 101 
    
PI 7.65 4.79 62.6 
 15. 3 7.99 52.3 
 22.9 10.3 44.9 
 26.8 13.2 49.5 
 30.6 16.4 53.5 
 
PAA : phthalamic acid ; PI : phthalimide ; TMS-PA : trimethylsilyl-phthalic acid. 
a
 Amount of PAA or PI (expressed in nmol) added to the urine of an unexposed subject and 
processed as described in Materials and Methods. Duplicates were prepared for each spiking 
level. 
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b
 Amount of total PA equivalents recovered (as TMS-PA) after sample processing of a urine 
spiked with PAA or PI and after subtracting baseline amounts of PA found in urine of the 
unexposed subject, which was 0.6025 nmol (calculated from the ratio of the intercept to slope 
of the calibration curve). 
c
 Percent of PAA or PI converted to TMS-PA after sample processing, as described in 
Materials and Methods, of a urine spiked with different amounts of PAA and PI.
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Table 4 
Recovery of PA, intra- and inter-day precision and accuracy from replicate analysis of daily prepared aliquots of a pool of urine from unexposed 
individuals spiked with PA at five different levels and previously prepared QC samples spiked at two levels (n = 20 replicates for each spiking 
level). 
    Intra-day variation
a
  Inter-day variation
b
 
Amount 
added 
(nmol)
c 
Recovery
d 
(%) 
RSD
e 
(%) 
 
Amount found
f 
(nmol) 
(mean ± SD
g
) 
Precision 
(% RSD
e
) 
Overall 
RSD
h
 
(%) 
Accuracy
i
 
(%) 
 
Amount found
f
 
(nmol) 
(mean ± SD
g
) 
Precision 
(% RSD
e
) 
Overall 
RSD
h
 
(%) 
Accuracy
i
 
(%) 
Spiked urine from unexposed 
persons 
    
  
   
  
1.33 95.8 11.3  1.28 ± 0.14 11.3 8.65 –4.22 
–0.48 
–2.41 
–3.73 
–1.41 
 1.28 ± 0.11 8.33 6.09 –4.00 
–0.08 
–2.27 
–3.65 
–1.64 
2.66 99.5 9.04  2.65 ± 0.24 9.04   2.66 ± 0.18 6.65  
3.99 97.6 7.08  3.90 ± 0.28 7.08   3.90 ± 0.21 5.39  
4.66 96.3 8.28  4.49 ± 0.37 8.28   4.49 ± 0.28 6.31  
5.33 98.6 9.29  5.25 ± 0.49 9.29   5.24 ± 0.31 5.99  
 QC spiked samples            
1.98 91.9 12.5  1.83 ± 0.23 12.5 10.14 –8.06 
–1.18 
 1.83 ± 0.16 8.64 6.87 –7.94 
–1.16 4.96 98.2 9.26  4.91 ± 0.45 9.26   4.91 ± 0.32 6.51  
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a 
Average variation between N replicates of the same level of spiking prepared and analyzed the same day.
 
b
 Average variation between N replicates of the same level of spiking prepared and analyzed on different days over a 22-day period. 
c
 Amount of PA (expressed in nmol) added at the different concentration levels to aliquots of a pool of urine from an unexposed individual. 
d
 Percent recovery of total PA amounts as TMS-PA (different levels) after addition of PA to urine from an unexposed individual and processed as 
described in Materials and Methods. 
e
 Precision or RSD: relative standard deviation for 20 replicates. 
f
 Recovered amount of total PA (as TMS-PA) after sample processing and calculated from calibration curves by subtracting baseline amounts of 
PA found in urine of the unexposed subject (calculated from the ratio of the intercept to slope of the calibration curve). 
g
 SD: standard deviation of N replicates. 
h
  Overall RSD: mean relative standard deviation with all spiked urine from unexposed persons combined (n = 100) and all QC samples 
combined (n = 40). 
i
 Accuracy, or percent relative error. 
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Table 5 
Creatinine adjusted urinary concentrations of total PA equivalents in workers during the course of a typical workweek following a spraying 
episode of folpet or harvest activities in a previously treated area, along with pre-seasonal concentrations. 
Workers
a Activities
b
 
 Urinary PA concentration (nmol/mmol creatinine) 
Shift 
Length
c
 
Pre-seasonal Workday 1
d
 Workday 2 Workday 3 Workday 4 Workday 5 
Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift Pre-shift Post-shift 
Worker 1 Spraying 4 h 268 655 2448 1152 2790 1557 3508 1252 1528 1120 1779 
 Harvest 6 h 268 846 1244 1293 1486 913 2496 1604 ns ns ns 
Worker 2 Spraying 6 h 108 152 312 588 561 636 435 195 162 135 246 
 Harvest 36 h 108 237 230 197 256 345 234 311 259 598 214 
Worker 3 Spraying 3 h 181 334 845 406 334 357 174 312 242 227 292 
 Harvest 38 h 181 126 216 219 155 130 409 275 771 310 124 
ns: no sample collected. 
a
 Each worker collected their urine void during a typical workweek involving spraying of folpet and harvest activities in a previously treated area. 
b
 Each worker performed both spraying and harvest activities, which were separated by a minimum of two weeks. 
c
 Total duration of spraying and harvest activities for each worker. 
d
 Folpet were sprayed and harvest activities were performed only on workday 1, except for worker 2, who harvested from workdays 1 to 3.
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Figure captions 
 
Fig. 1 Chemical structure of (a) folpet and its main ring-metabolites: (b) phthalimide, (c) 
phthalamic acid and (d) phthalic acid. 
 
Fig. 2 Representative chromatograms of TMS-PA and TMS-IS in blank human urine spiked with 
12.1 µmol/L of PA and 6.72 µmol/L of p-methylhippuric acid (IS), along with the mass spectra and 
structure of both TMS derivatives. 
 
Fig. 3 Representative chromatograms of TMS-PA and TMS-IS in human urine: (a) blank urine 
spiked with 12.1 µmol/L of PA and 6.72 µmol/L of methylhippuric acid (IS); (b) urine from a non-
occupationally exposed person spiked with 6.72 µmol/L of IS; (c) urine sample of a volunteer orally 
dosed with folpet (9 h following absorption) spiked with 6.72 µmol/L of IS; (d) urine sample of a 
volunteer dermally dosed with folpet (24 h following application) spiked with 6.72 µmol/L of IS; 
(e) urine sample of a farmer spraying folpet (13 h following the beginning of spraying). 
 
Fig. 4 Concentration-time profiles of total PA equivalents (mean ± SD) in the urine of volunteers 
administered folpet by the oral (1 mg/kg) (-●-) or dermal (10 mg/kg) (-○-) route. 
 
 Figure 1 
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 Figure 2 
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 Figure 3 
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Figure 4 
 
 
